Your session is about to expire
← Back to Search
Unknown
Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers
Phase 1
Waitlist Available
Research Sponsored by Vanda Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 96 hours
Awards & highlights
No Placebo-Only Group
Summary
This trial compares two tablets, VHX-896 and Iloperidone, to see if they work the same way in healthy people. Healthy volunteers are used to ensure clear results. The study measures how similarly the body absorbs and processes both tablets. Iloperidone is a medication approved several years ago for the treatment of schizophrenia in adults.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 96 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~96 hours
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Assessment of Safety and Tolerability of a single dose of VHX-896
Bioequivalence between VHX-896 tablets relative to iloperidone tablets
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Sequence B: Iloperidone then VHX-896Experimental Treatment1 Intervention
Group II: Sequence A: VHX-896 then iloperidoneExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
VHX-896 and iloperidone
2021
Completed Phase 1
~30
Iloperidone and VHX-896
2021
Completed Phase 1
~30
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Vanda PharmaceuticalsLead Sponsor
63 Previous Clinical Trials
19,202 Total Patients Enrolled